HeartFlow Launches Advanced Interactive Plaque Analysis Platform for Evaluating Patient Risk in Suspected Coronary Artery Disease – Medical Device News Magazine

**HeartFlow Launches Advanced Interactive Plaque Analysis Platform for Evaluating Patient Risk in Suspected Coronary Artery Disease** *Medical Device News Magazine*...

# A Look Inside Canary Wharf’s Advanced Infectious Disease Testing Facility In the heart of London’s bustling financial district, Canary...

**Bon Secours Mercy Health and Philips Announce Long-Term Strategic Partnership** In a significant move poised to reshape the landscape of...

**Bon Secours Mercy Health and Philips Announce Multi-Year Strategic Partnership** *Medical Device News Magazine* In a significant move poised to...

**Novocuff Secures $26 Million in Oversubscribed Series A Funding to Enhance Preterm Birth Prevention Technology** *Medical Device News Magazine* In...

# 9 Innovative Applications of AI in Medical Device Development Artificial Intelligence (AI) is revolutionizing various sectors, and the field...

**Ideal Medical Solutions Honored at 2024 Medical Device Network Excellence Awards** In a remarkable celebration of innovation and excellence in...

**Government Initiates Program to Enhance Local Production of 113 Cost-Effective Medical Devices, Aiming to Reduce Import Reliance** In a significant...

**Digestiva Secures $18.4 Million in Series A Funding – Reported by Medical Device News Magazine** In a significant development within...

**Mabwell Gains NMPA Approval for Clinical Trial of Innovative Nectin-4 Targeting ADC in Triple-Negative Breast Cancer** In a significant stride...

**Immediate Medicare Coverage Announced for Designated Medical Breakthrough Devices by Knobbe Medical** In a landmark decision poised to revolutionize the...

**WHO Introduces MeDevIS: A Cutting-Edge Platform for Worldwide Medical Device Information** In a significant stride towards enhancing global healthcare, the...

# Comprehensive EDA Guidelines on Recall Classification Rules | RegDesk In the realm of medical devices and pharmaceuticals, ensuring product...

# Guidelines on Recall Classification Rules by the EDA ## Introduction The European Medicines Agency (EMA) and the U.S. Food...

# Comprehensive EDA Guidelines for Initiating Product Recalls | RegDesk In the fast-paced world of product manufacturing and distribution, ensuring...

# Exploring the Limits of Our Molecular Understanding In the vast and intricate world of biology, the molecular level serves...

**Applications of Precision Medicine in Healthcare** Precision medicine, also known as personalized medicine, is revolutionizing the healthcare landscape by tailoring...

# Comprehensive Guide to Breathing Apparatus Manufacturing ## Introduction Breathing apparatuses are critical safety devices designed to provide respiratory protection...

**The Future of Continuous Glucose Monitors: Analyzing Global Expansion and US Market Dominance** Continuous Glucose Monitors (CGMs) have revolutionized diabetes...

**The Future of Continuous Glucose Monitors: Global Expansion and Dominance in the US Market** Continuous Glucose Monitors (CGMs) have revolutionized...

**Global Expansion and US Dominance in the Future of Continuous Glucose Monitors** Continuous Glucose Monitors (CGMs) have revolutionized diabetes management,...

# Guidelines for On-Site Inspections Under China’s Good Supply Practice (GSP) Issued ## Introduction China’s pharmaceutical industry has seen rapid...

# Guideline for On-Site Inspections Under China’s Good Supply Practice (GSP) Issued ## Introduction China’s pharmaceutical industry has been undergoing...

**China’s New Generalized System of Preferences to Take Effect on July 1, 2024** In a significant move aimed at bolstering...

**Implementation of China’s New Generalized System of Preferences (GSP) Set for July 1, 2024** China is set to implement a...

**Implementation of China’s New Generalized System of Preferences (GSP) Starting July 1, 2024** China is set to implement a new...

**Implementation of China’s New Generalized System of Preferences (GSP) Effective July 1, 2024** On July 1, 2024, China will implement...

**Nexalin Technology Sets Price for $5.2 Million Public Offering** In a significant move within the medical technology sector, Nexalin Technology,...

**Essential Tips for Preventing Running Injuries: Insights from Medical Device News Magazine** Running is one of the most popular forms...

**Strategies for Reducing Preventable Injuries to Enhance Healthcare in Canada** Preventable injuries represent a significant burden on the Canadian healthcare...

NeuroBo Pharmaceuticals Initiates Phase 2a Clinical Trial to Assess DA-1241 for NASH Treatment – Medical Device News Magazine

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company, has recently announced the initiation of a Phase 2a clinical trial to evaluate the efficacy and safety of their investigational drug, DA-1241, for the treatment of non-alcoholic steatohepatitis (NASH). This exciting development brings hope to the millions of people worldwide who suffer from this progressive liver disease.

NASH, a severe form of fatty liver disease, is characterized by the accumulation of fat in the liver, inflammation, and liver cell damage. If left untreated, it can progress to more severe conditions such as cirrhosis, liver failure, and even liver cancer. Currently, there are no approved medications specifically designed to treat NASH, making this clinical trial a significant step forward in addressing this unmet medical need.

DA-1241 is a novel, orally administered small molecule that targets multiple pathways involved in the development and progression of NASH. It works by modulating the activity of key enzymes and receptors responsible for lipid metabolism, inflammation, and fibrosis in the liver. By targeting these pathways simultaneously, DA-1241 aims to provide a comprehensive therapeutic approach to NASH treatment.

The Phase 2a clinical trial will enroll approximately 100 patients with biopsy-confirmed NASH across multiple sites in the United States. The primary objective of the study is to evaluate the effect of DA-1241 on liver fat content measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) after 12 weeks of treatment. Secondary objectives include assessing changes in liver enzymes, fibrosis markers, and other relevant biomarkers associated with NASH.

Dr. John Doe, Chief Medical Officer of NeuroBo Pharmaceuticals, expressed his enthusiasm for the trial, stating, “We are excited to initiate this Phase 2a clinical trial to evaluate the potential of DA-1241 in treating NASH. With its unique mechanism of action and promising preclinical data, we believe DA-1241 has the potential to address the underlying causes of NASH and provide meaningful benefits to patients.”

The trial will also evaluate the safety and tolerability of DA-1241, with adverse events and laboratory assessments closely monitored throughout the study. NeuroBo Pharmaceuticals aims to gather comprehensive data on the drug’s efficacy, safety, and pharmacokinetics to support further development and potential regulatory approval.

The initiation of this Phase 2a clinical trial marks a significant milestone for NeuroBo Pharmaceuticals and the field of NASH research. If successful, DA-1241 could potentially become the first approved medication specifically indicated for NASH treatment, offering hope to patients and healthcare providers alike.

NASH is a growing global health concern, with an estimated prevalence of 3-12% in the general population. It is closely associated with obesity, type 2 diabetes, and metabolic syndrome, making it a significant burden on healthcare systems worldwide. The lack of approved treatments underscores the urgent need for innovative therapies like DA-1241 to address this unmet medical need.

NeuroBo Pharmaceuticals’ commitment to advancing the development of DA-1241 for NASH treatment is commendable. By targeting multiple pathways involved in NASH pathogenesis, this investigational drug holds great promise in improving patient outcomes and reducing the burden of this debilitating liver disease.

As the Phase 2a clinical trial progresses, the medical community eagerly awaits the results that will shed light on the potential of DA-1241 as a breakthrough therapy for NASH. If successful, it could pave the way for a new era in NASH treatment and bring hope to millions of individuals affected by this silent epidemic.